Leukaemia Breakthrough
A therapy devised by Weizmann Institute immunologist Prof. Zelig Eshhar for the treatment of a blood cancer called acute lymphoblastic leukaemia showed a 94% success rate in early-stage clinical trials in a study released in 2016. In the trial, cancers in 27 out of 29 patients went into remission or disappeared altogether. All of the patients in the study were considered “end-stage”—people with advanced cancers who have exhausted all other treatment options.